z-logo
Premium
Dupilumab for pediatric prurigo nodularis: A case report
Author(s) -
Fachler Tahel,
Maria Faitataziadou Sofia,
MolhoPessach Vered
Publication year - 2020
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.14464
Subject(s) - prurigo nodularis , dupilumab , medicine , dermatology , prurigo , atopic dermatitis , refractory (planetary science) , rescue therapy , girl , dermatologic agents , surgery , psychology , developmental psychology , physics , astrobiology , microbiology and biotechnology , biology , antibiotics
Herein we report on a 9‐year‐old girl with recalcitrant prurigo nodularis unresponsive to multiple standard treatments. She was started on dupilumab therapy with rapid improvement in pruritus within 2 weeks and near complete regression of lesions at 3 months. Dupilumab should be considered as an off‐label treatment for refractory prurigo nodularis in children.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here